Skip to main content
AnnovisBioAdvance NewsPortfolio News

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

By June 9, 2022November 1st, 2024No Comments

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Annovis Bio’s Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company’s Lead Compound, to Treat Neurodegenerative Diseases

With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries

See more here